XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 2,175 $ 2,165
Accounts receivables, net of allowance for credit losses of $91 million and $90 million as of March 31, 2022 and December 31, 2021 4,253 4,529
Inventories 4,012 3,818
Prepaid expenses 1,064 1,075
Other current assets 933 965
Assets held for sale 13 19
Total current assets 12,451 12,573
Deferred income taxes 637 596
Other non-current assets 472 515
Property, plant and equipment, net 5,932 5,982
Operating lease right-of-use assets 464 495
Identifiable intangible assets, net 7,116 7,466
Goodwill [1] 19,986 20,040
Total assets 47,059 47,666
Current liabilities:    
Short-term debt 2,077 1,426
Sales reserves and allowances 3,807 4,241
Accounts payables 1,750 1,686
Employee-related obligations 481 563
Accrued expenses 2,597 2,208
Other current liabilities 900 903
Total current liabilities 11,613 11,027
Long-term liabilities:    
Deferred income taxes 666 784
Other taxes and long-term liabilities 3,288 2,578
Senior notes and loans 20,840 21,617
Operating lease liabilities 393 416
Total long-term liabilities 25,186 25,395
Commitments and contingencies, see note 10
Total liabilities 36,799 36,422
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; March 31, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively. 57 57
Additional paid-in capital 27,587 27,561
Accumulated deficit (11,484) (10,529)
Accumulated other comprehensive loss (2,687) (2,683)
Treasury shares as of March 31, 2022 and December 31, 2021: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 9,344 10,278
Non-controlling interests 916 966
Total equity 10,260 11,244
Total liabilities and equity $ 47,059 $ 47,666
[1] Accumulated goodwill impairment as of March 31, 2022 and December 31, 2021 was approximately $25.6 billion.